Considerable time and expense are often spent gathering and analyzing all the relevant data for confident, strategic decisions for your generics portfolio, best-fit active pharmaceutical ingredient (API) suppliers, and most feasible partners and markets to expand your business.
Newport, a Cortellis solution, lets you strategically develop your generics portfolio, find API suppliers, gain insight on when drugs go off patent, penetrate new markets, identify partners, and monitor your competition.
Quickly and thoroughly research new product and company opportunities using a single source of data on patents, sales, pack price, consumption, Paragraph IV patent challenges, API, market share, companies and launches. Gain a reliable, comprehensive resource for advanced product targeting, global API intelligence and strategic business development with integrated data from Newport.
"Newport has been a great investment for us, saving us time and money, while improving productivity."
Efficiently access and analyze data to quickly develop a short list of potential portfolio candidates or partners meeting your specific criteria for drug characteristics, partner experience and capabilities that fit with your strategy.
"One great thing about Newport is the distinction between confirmed and unconfirmed APIs – so we can see the complete picture straight away."
Make faster, better decisions using proprietary analytics, based on primary research, such as the Newport Constraint Date (covering 36 countries), API Availability Rating, and API Manufacturing Status. Get deeper insight into when drugs go off patent, the competitiveness of the generic market for a given API and capabilities of API manufacturers.
"Newport delivers information from across all of the world’s pharmaceutical markets, which can be accessed seamlessly…filtered out and narrowed down to the exact detail of interest."
Have greater confidence in strategy decisions using a solution that provides market, API and patent intelligence in a single platform. This helps you determine the drug candidates with the greatest probability of success as well as API manufacturers best suited to your needs.
"Newport is embedded in my team’s workflow and harnessed … every day. [We use] Newport’s 'Advanced Search' function … to narrow down specific information and eliminate irrelevant data."
Clarivate experts bring together a unique combination of Cortellis content (and other available data sources) with experienced consultants and proprietary methodologies to drive life sciences innovation – faster, with independent objectivity, for better results. Our experts deliver you unrivaled data science expertise, evidence-based consulting and independent advice across the pharmaceutical research and development value chain.
Select a reliable, experienced API supplier using expertly researched and validated API manufacturing intelligence, including regulatory filing status, inspection dates, and more.
Quickly and accurately identify a short list of potential portfolio candidates with just a few clicks.
Trusted by 85% of the world’s top 20 generic and API manufacturers and 70% of the top 10 fastest-growing generics companies.
Small molecules and biologics with synthesis schemes
Manufacturers and marketers
US, JP and SK DMF, COS and GMP certificates
Regions' sales data sourced
Countries' launch data available
Our accredited global alliance program delivers value-added solutions by combining offerings from Clarivate with other technology and service providers. Partner with us to drive profitable growth, increase revenue and deliver greater value to your customers.
Receive daily insights on the latest biopharma news and medical technology advances to better inform crucial R&D decisions at the earliest research stages.
Contact us to schedule a demo of Newport, a Cortellis solution.